[{"id":"e61a842e-3393-4ae3-9685-c52db2616f42","acronym":"4CAST","url":"https://clinicaltrials.gov/study/NCT04947189","created_at":"2021-07-01T14:54:41.667Z","updated_at":"2024-07-02T16:35:33.448Z","phase":"Phase 1b","brief_title":"Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer","source_id_and_acronym":"NCT04947189 - 4CAST","lead_sponsor":"St Vincent's Hospital, Sydney","biomarkers":" HER-2 • PGR • AR","pipe":" | ","alterations":" HR positive • HER-2 negative • AR positive • EGFR positive","tags":["HER-2 • PGR • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • AR positive • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • dexamethasone • seviteronel (INO-464)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-10-16"},{"id":"74bb0dc5-6670-4a97-bed0-b1c45b0dfe37","acronym":"CLARITY-01","url":"https://clinicaltrials.gov/study/NCT02580448","created_at":"2021-01-18T12:30:49.015Z","updated_at":"2024-07-02T16:37:03.253Z","phase":"Phase 1/2","brief_title":"CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)","source_id_and_acronym":"NCT02580448 - CLARITY-01","lead_sponsor":"Innocrin Pharmaceutical","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e seviteronel (INO-464)"],"overall_status":"Completed","enrollment":" Enrollment 175","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2019-02-01"},{"id":"25170b14-2ea2-49b0-acfc-f00d60de235f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02130700","created_at":"2021-01-18T09:53:00.309Z","updated_at":"2024-07-02T16:37:10.952Z","phase":"Phase 2","brief_title":"Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer","source_id_and_acronym":"NCT02130700","lead_sponsor":"Innocrin Pharmaceutical","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • seviteronel (INO-464)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 09/01/2017","primary_completion_date":" 09/01/2017","study_txt":" Completion: 11/01/2017","study_completion_date":" 11/01/2017","last_update_posted":"2018-05-07"}]